Immunome Inc. (IMNM) income statement
IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$15.69−0.92 (-5.54%)
Close on Nov 20, 2026Market cap $1.78BP/E –Yield –
Immunome Inc. financial ratios
See a number that looks wrong?
Close on Nov 20, 2026Market cap $1.78BP/E –Yield –
See a number that looks wrong?
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Margins | ||||||||
| Operating margin | -3,228.8% | -3,382.4% | -781.4% | – | – | – | – | – |
| EBITDA margin | -3,193.3% | -3,365.0% | -778.1% | – | – | – | – | – |
| Net profit margin | -3,060.0% | -3,240.4% | -761.9% | – | – | – | – | – |
| Free cash flow margin | -2,890.1% | -1,304.8% | -59.9% | – | – | – | – | – |
| Returns on capital | ||||||||
| Return on equity | -52.1% | -194.6% | -156.5% | -115.7% | -55.2% | -624.2% | 34.3% | – |
| Return on assets | -46.0% | -150.7% | -123.8% | -90.0% | -48.2% | -71.9% | -206.4% | – |
| Return on tangible assets | -46.0% | -150.7% | -123.8% | -90.0% | -48.2% | -71.9% | -206.4% | – |
| Return on invested capital | – | – | – | – | – | -489.4% | – | – |
| Return on capital employed | -54.4% | -195.6% | -152.7% | -113.7% | -56.2% | -54.6% | -304.8% | – |
| Return on total capital | – | – | – | – | – | -29.3% | – | – |
| NOPAT | -$177.05M | -$241.58M | -$86.53M | -$29.15M | -$19.91M | -$9.69M | -$8.17M | – |
| Cash flow quality | ||||||||
| OCF / Sales | -2,750.6% | -1,225.5% | -54.0% | – | – | – | – | – |
| OCF / Net income | 0.90 | 0.38 | 0.07 | 0.78 | 0.74 | 0.68 | 0.92 | – |
| FCF / OCF | 105.1% | 106.5% | 111.0% | 100.9% | 100.4% | 104.8% | 102.4% | – |
| FCF / Net income | 0.94 | 0.40 | 0.08 | 0.78 | 0.74 | 0.71 | 0.94 | – |
| FCF / EBITDA | 90.5% | 38.8% | 7.7% | 79.3% | 74.9% | 110.6% | 101.0% | – |
| Unlevered free cash flow | -$200.60M | -$117.97M | -$8.40M | -$28.94M | -$18.31M | -$12.70M | -$9.80M | – |
| Levered free cash flow | -$200.60M | -$117.97M | -$8.40M | -$28.94M | -$18.31M | -$12.72M | -$9.83M | – |
| Efficiency | ||||||||
| Asset turnover | 0.02 | 0.05 | 0.16 | – | – | – | – | – |
| Fixed asset turnover | 0.56 | 1.48 | 10.18 | – | – | – | – | – |
| CapEx to revenue | 139.5% | 79.3% | 5.9% | – | – | – | – | – |
| CapEx to OCF | -5.1% | -6.5% | -11.0% | -0.86% | -0.43% | -4.8% | -2.4% | – |
| CapEx to depreciation | 3.93 | 4.58 | 1.82 | 0.59 | 0.10 | 0.78 | 0.38 | – |
| Liquidity | ||||||||
| Current ratio | 14.69 | 4.08 | 6.63 | 3.09 | 5.82 | 14.12 | 1.88 | – |
| Quick ratio | 14.69 | 4.08 | 6.63 | 3.09 | 5.82 | 14.12 | 1.88 | – |
| Cash ratio | 14.53 | 4.00 | 6.33 | 2.79 | 5.07 | 13.12 | 1.59 | – |
| Working capital | $615.79M | $167.03M | $122.87M | $15.32M | $46.91M | $39.86M | $1.46M | – |
| Net current asset value | $611.93M | $162.26M | $116.05M | $15.26M | $46.90M | $39.71M | $1.33M | – |
| Leverage | ||||||||
| Total debt | – | – | – | – | – | $500.00K | – | – |
| Net debt | – | – | – | – | – | -$39.37M | – | – |
| Debt / Equity | – | – | – | – | – | 0.01 | – | – |
| Debt ratio | – | – | – | – | – | 1.1% | – | – |
| Assets to equity | 1.08 | 1.33 | 1.24 | 1.44 | 1.20 | 1.08 | -0.14 | – |
| Long-term debt to assets | – | – | – | – | – | 0.30% | – | – |
| Long-term debt to equity | – | – | – | – | – | 0.00 | – | – |
| Total debt / Capitalization | – | – | – | – | – | 1.2% | – | – |
| Long-term debt / Capitalization | – | – | – | – | – | 0.32% | – | – |
| Net debt / EBITDA | – | – | – | – | – | 3.42 | – | – |
| Total debt / EBITDA | – | – | – | – | – | -0.04 | – | – |
| Cash flow to debt | – | – | – | – | – | -2,426.8% | – | – |
| Interest coverage | ||||||||
| EBIT / Interest expense | – | – | – | – | – | -583.86 | -224.96 | – |
| EBITDA / Interest expense | – | – | – | – | – | -547.90 | -211.59 | – |
| (EBITDA − CapEx) / Interest expense | – | – | – | – | – | -575.81 | -216.65 | – |
| Per share | ||||||||
| Revenue per share | 0.06 | 0.14 | 0.32 | – | – | – | – | – |
| EPS (basic) | -2.43 | -5.00 | -5.38 | -3.09 | -2.14 | -5.26 | -9.55 | – |
| EPS (diluted) | -2.43 | -5.00 | -5.38 | -3.09 | -2.14 | -5.26 | -9.55 | – |
| Book value per share | 5.61 | 2.81 | 2.77 | 1.37 | 3.98 | 3.89 | -32.41 | – |
| Tangible book value per share | 5.61 | 2.81 | 2.77 | 1.37 | 3.98 | 3.89 | -32.41 | – |
| Cash per share | 5.78 | 3.37 | 3.20 | 1.68 | 4.07 | 3.75 | 2.40 | – |
| Operating cash flow per share | -1.69 | -1.72 | -0.17 | -2.37 | -1.50 | -1.14 | -8.73 | – |
| Free cash flow per share | -1.77 | -1.83 | -0.19 | -2.39 | -1.51 | -1.20 | -8.95 | – |
| CapEx per share | 0.09 | 0.11 | 0.02 | 0.02 | 0.0065 | 0.06 | 0.21 | – |
| Valuation at period end | ||||||||
| Market cap | $1.97B | $641.68M | $130.57M | $26.80M | $156.73M | $10.89M | – | – |
| Enterprise value | $1.70B | $401.55M | $39.93M | -$276.02K | $100.49M | $4.64M | – | – |
| P/S | 284x | 71.0x | 9.3x | – | – | – | – | – |
| P/B | 3.1x | 3.5x | 1.1x | 1.6x | 3.3x | 0.3x | – | – |
| P/TBV | 3.1x | 3.5x | 1.1x | 1.6x | 3.3x | 0.3x | – | – |
| P/OCF | -10.3x | -5.8x | -17.3x | -0.9x | -8.6x | -0.9x | – | – |
| EV/Sales | 245x | 44.4x | 2.8x | – | – | – | – | – |
| EV/EBITDA | – | – | – | 0.0x | – | – | – | – |
| EV/EBIT | – | – | – | 0.0x | – | – | – | – |
| EV/OCF | -8.9x | -3.6x | -5.3x | 0.0x | -5.5x | -0.4x | – | – |
| EV/FCF | – | – | – | 0.0x | – | – | – | – |
| Earnings yield | -10.8% | -45.7% | -81.8% | -137.7% | -15.8% | -163.8% | – | – |
| FCF yield | -10.2% | -18.4% | -6.4% | -108.0% | -11.7% | -116.8% | – | – |
| Cost structure | ||||||||
| R&D to revenue | 2,554.2% | 1,432.8% | 164.7% | – | – | – | – | – |
| Stock-based comp to revenue | 370.1% | 174.2% | 44.4% | – | – | – | – | – |
| Per employee | ||||||||
| Total employees | 177 | 118 | 55 | 37 | 39 | 23 | 23 | 23 |
| Revenue per employee | $39.21K | $76.62K | $254.87K | – | – | – | – | – |
| Operating profit per employee | -$1.27M | -$2.59M | -$1.99M | -$997.32K | -$646.26K | -$533.09K | -$449.91K | – |
| Net income per employee | -$1.20M | -$2.48M | -$1.94M | -$997.19K | -$633.62K | -$775.52K | -$454.09K | – |
| Free cash flow per employee | -$1.13M | -$999.72K | -$152.71K | -$782.11K | -$469.36K | -$553.04K | -$427.52K | – |
| Growth | ||||||||
| Revenue 1Y growth | -23.2% | -35.5% | – | – | – | – | – | – |
| EBIT 1Y growth | 26.7% | -179.2% | -196.8% | -46.4% | -105.6% | -18.5% | – | – |
| EBITDA 1Y growth | 27.1% | -178.9% | -199.0% | -49.2% | -112.5% | -18.2% | – | – |
| Net income 1Y growth | 27.5% | -174.3% | -189.5% | -49.3% | -38.5% | -70.8% | – | – |
| Diluted EPS 1Y growth | 51.4% | 7.1% | -74.1% | -44.4% | 59.3% | 44.9% | – | – |
| Operating cash flow 1Y growth | -72.3% | -1,364.0% | 73.6% | -57.4% | -50.2% | -26.4% | – | – |
| Free cash flow 1Y growth | -70.1% | -1,304.5% | 71.0% | -58.1% | -43.9% | -29.4% | – | – |
| CapEx 1Y growth | 35.0% | 763.2% | 235.1% | 213.9% | -86.5% | 151.5% | – | – |
| CapEx 3Y CAGR | 239.3% | 349.5% | 12.3% | 2.1% | – | – | – | – |
| CapEx 5Y CAGR | 75.2% | 98.5% | – | – | – | – | – | – |
| Total assets 1Y growth | 184.4% | 61.7% | 517.7% | -58.5% | 30.1% | 779.9% | – | – |
| Total assets 3Y CAGR | 205.1% | 60.7% | 49.4% | 68.1% | – | – | – | – |
| Total assets 5Y CAGR | 72.7% | 116.4% | – | – | – | – | – | – |
| Total equity 1Y growth | 250.1% | 51.1% | 619.9% | -65.4% | 16.5% | 216.0% | -41.4% | – |
| Total equity 3Y CAGR | 236.5% | 55.5% | 42.6% | – | – | – | – | – |
| Total equity 5Y CAGR | 72.7% | – | – | – | – | – | – | – |
Every figure here is calculated from standardized financial statements — hover a row name for the formula — not reported by the company. Valuation multiples use the closing price at the end of that period, not today's price.